Jefferies initiates Veracyte stock with buy on diagnostics growth By Investing.com

Jefferies initiated Veracyte at Buy with a $45 target, citing 16% revenue growth to $517 million, 72% gross margin, and EBITDA of $84.4 million over the last 12 months. The article also notes upbeat earnings momentum, with 7 analysts raising estimates and recent Q4 2025 results beating consensus on both EPS ($0.53 vs. $0.39) and revenue ($141 million vs. $132.43 million). Longer-term upside is tied to TrueMRD and other minimal residual disease opportunities, though other brokers remain mixed with targets ranging from $37 to $53.

Analysis

VCYT screens as a rare diagnostics compounder where the market is still valuing the installed base more like a mature tools company than a platform with multiple shots on goal. The key second-order effect is that reimbursement protection in one flagship franchise can subsidize expansion into adjacent, higher-growth tests without forcing near-term margin dilution; that makes the company’s growth profile more durable than headline revenue alone suggests.

The bigger debate is not whether current growth is good, but whether the market is underpricing the option value of TrueMRD and other MRD entry points. If even one indication scales, the mix shift toward longitudinal surveillance could expand TAM meaningfully and lift recurring test density, but the adoption curve is likely uneven because payor coverage, clinical guidelines, and physician workflow integration will be the gating variables. That argues for a multi-quarter rather than one-earnings-cycle view.

The contrarian risk is that consensus is extrapolating the current Decipher/Afirma strength too linearly while underestimating concentration risk: roughly all of the value today is anchored to two products, so any reimbursement hiccup or competitive encroachment would compress the multiple fast. MS’s weaker stance is a reminder that valuation compression can persist even when fundamentals improve if the market decides the MRD story is still too early to capitalize.

Near term, the catalyst stack is favorable: upward estimate revisions, evidence of cash generation, and any incremental MRD data or coverage updates can drive multiple expansion over the next 3-9 months. But the stock likely needs repeated proof points, not just a single launch announcement, to justify a sustained rerating from a 3x EV/Sales starting point.

Key Decisions for Investors

• Long VCYT on weakness with a 3-6 month horizon; use pullbacks toward the lower end of the analyst range as entry, targeting rerating if MRD adoption or coverage news de-risks the growth bridge. Risk/reward: ~15-25% upside on multiple expansion versus low-teens downside if execution remains steady but the market stays skeptical.
• Pair trade: long VCYT / short a lower-margin diagnostics peer with weaker reimbursement visibility over the next 1-2 quarters. The thesis is that profitable, evidence-backed platforms should outperform commoditized test franchises as investors reward cash conversion and coverage durability.
• Buy VCYT call spreads 6-12 months out to capture MRD optionality without paying full delta for a slow adoption curve. Prefer structures that profit from a move into the high-$40s while capping premium at risk in case the market waits for formal reimbursement milestones.
• Trim or avoid adding on strength ahead of any launch/data headline if the stock rerates above the upper analyst target band; the market may front-run a future revenue stream that will likely take multiple quarters to evidence.